Skip to content

Study · Systematic review · n = 12,785 · 2025

3 results

Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Abdullah A, Sagreeka FNU, Aniket GA, Lal R, Geeta FNU, Bai A, Ahmed GU, Raza AA, Shaikh VF, Sanaullah O, Sabahat SE, Ghori AK, Bhutto SH, Tesfaye M

Endocrinology, diabetes & metabolism1 Nov 2025Cited by 3 (Europe PMC)

PMID41276951 (opens in a new tab)PMCIDPMC12640882 (opens in a new tab)DOI10.1002/edm2.70136 (opens in a new tab)PepBankPUB-41276951
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundChronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-like peptide-1 receptor agonist, has shown favourable cardiorenal effects in T2DM patients, prior meta-analyses were limited by small sample sizes and few studies. This updated meta-analysis includes both diabetic and non-diabetic CKD patients, incorporates recently published RCTs and addresses gaps in the literature to enhance result generalizability.MethodsMEDLINE, Embase and Cochrane CENTRAL were searched from inception to May 2025 following PRISMA and AMSTAR guidelines. Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included. Primary outcomes included cardiovascular mortality, major adverse cardiovascular events (MACE), major kidney-related adverse events, nonfatal myocardial infarction and nonfatal stroke. Risk of bias was assessed using Cochrane RoB 2.0.ResultsFive RCTs involving 12,785 participants were included. The findings showed that semaglutide substantially decreased major kidney-related adverse events (defined as a composite outcome encompassing the onset of kidney failure (including long-term dialysis, kidney transplantation or a sustained eGFR reduction to 2), a sustained 50% or greater reduction in eGFR from baseline, or death due to kidney-related causes) (RR: 0.79; 95% CI: 0.71-0.87; p 2 = 0%), cardiovascular mortality (RR: 0.74; 95% CI: 0.62-0.88; p = 0.0008; I2 = 36%) and MACE (defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) (RR: 0.78; 95% CI: 0.70-0.87; p 2 = 0%).ConclusionSemaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Further research is needed to confirm its effects in non-diabetic CKD populations.Trial registrationInternational Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD420251019235.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with CKD, with or without type 2 diabetes, semaglutide reduced major kidney-related adverse events compared with placebo or standard care.

    In plain wordsIn adults with chronic kidney disease, semaglutide lowered the risk of serious kidney events compared with placebo or standard care.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor kidney-related adverse events
    Study

    n = 12,785

    Comparator
    Placebo or standard care
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    RR
    0.79 NA
    major kidney-related adverse events

    Source sentences

    Summary
    semaglutide substantially decreased major kidney-related adverse events (defined as
    3 context sentences
    Summary · context
    (RR: 0.79; 95% CI: 0.71-0.87; p 2 = 0%)
    Summary · context
    Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included.
    Summary · context
    Five RCTs involving 12,785 participants were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with CKD, with or without type 2 diabetes, semaglutide reduced cardiovascular mortality compared with placebo or standard care.

    In plain wordsIn adults with chronic kidney disease, semaglutide lowered the risk of death from heart and blood vessel disease compared with placebo or standard care.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular mortality
    Study

    n = 12,785

    Comparator
    Placebo or standard care
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    0.74 NA
    cardiovascular mortality

    Source sentences

    Summary
    cardiovascular mortality (RR: 0.74; 95% CI: 0.62-0.88; p = 0.0008; I2 = 36%)
    2 context sentences
    Summary · context
    Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included.
    Summary · context
    Five RCTs involving 12,785 participants were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with CKD, with or without type 2 diabetes, semaglutide reduced MACE compared with placebo or standard care.

    In plain wordsIn adults with chronic kidney disease, semaglutide lowered the risk of major heart and stroke events compared with placebo or standard care.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n = 12,785

    Comparator
    Placebo or standard care
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    0.78 NA
    MACE

    Source sentences

    Summary
    and MACE (defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke)
    3 context sentences
    Summary · context
    (RR: 0.78; 95% CI: 0.70-0.87; p 2 = 0%)
    Summary · context
    Studies comparing semaglutide with placebo or standard care in adults (≥ 18 years) with CKD, with or without T2DM were included.
    Summary · context
    Five RCTs involving 12,785 participants were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.